Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Botulinum purified neurotoxin, Type A · 1 trial · 1 indication
The primary safety analysis was the calculation of the proportion of subjects with at least one adverse event that occurred from Day 0 through Day 365.
| Arm | Type | Description |
|---|---|---|
| Botulinum neurotoxin, Type A | EXPERIMENTAL | DWP-450 (Botulinum purified neurotoxin, Type A) Injection |
| Name | Type | Description |
|---|---|---|
| Botulinum purified neurotoxin, Type A | BIOLOGICAL | The subject is to be injected intra-muscularly into a total of five sites: the mid-line of the procures muscle, the inferomedial aspect of each corrugator muscle and the superior middle aspect of each corrugator, at least 1 cm above the bony orbital rim. Each site is injected with 0.1 ml (4U), for a total of 20 U and 0.5 ml. |
Inclusion Criteria (A subject must meet all of the following inclusion criteria in order to be eligible for enrollment in the study): * Subjects must be an adult 18 years of age or over * Subject is able to provide informed consent and comply with study instructions * Subject has moderate to severe...
Botulinum purified neurotoxin, Type A is being studied by Evolus, Inc. for the treatment of glabellar frown lines, the vertical lines between the eyebrows. The development program in this indication has reached Phase 2, and the clinical work to date has focused on evaluating injection of the neurotoxin in adults with glabellar lines.
Botulinum purified neurotoxin, Type A targets SNAP25, a hydrolytic enzyme. By acting on SNAP25, the neurotoxin interferes with the protein machinery involved in neurotransmitter release. This target class, a hydrolytic enzyme, is the basis for the molecule's pharmacological activity in the glabellar frown line program.
Botulinum purified neurotoxin, Type A is being developed by Evolus, Inc., which trades under the ticker EOLS. The company is advancing the neurotoxin as a treatment for glabellar frown lines, and the program has reached Phase 2 clinical development.
Botulinum purified neurotoxin, Type A is in Phase 2 development for glabellar frown lines. It is an investigational product and is not approved for this use. The Phase 2 program consists of one completed trial, and no trials in this program are currently active.
Botulinum purified neurotoxin, Type A has been evaluated in one Phase 2 trial, NCT02184988, titled Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar Lines. The trial was completed in the United States and enrolled 352 participants aged 18 years and older, including healthy volunteers.
Yes. DWP-450 is another name for botulinum purified neurotoxin, Type A. The Phase 2 trial NCT02184988, which studied injection of the neurotoxin to treat glabellar lines, refers to the product as DWP-450, so searches for either name point to the same Evolus, Inc. development program.